United States Glucagon-Like Peptide-1 (GLP-1) Agonists Market Insight
Published: 10 June 2026 | Report Format: Electronic (PDF)
United States GLP-1 agonists market is expected to expand at a rate of 12.0% owing to the rising prevalence of obesity and type 2 diabetes, increasing adoption of advanced metabolic therapies, growing insurance coverage
United States Glucagon-Like Peptide-1 (GLP-1) Agonists Market Insights Forecasts to 2035
- The United States GLP-1 Agonists Market Size Was Estimated at USD 48.0 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.0% from 2025 to 2035
- The United States GLP-1 Agonists Market Size is Expected to Rise Around USD 149.1 Billion by 2035
Notable Insights for the United States GLP-1 Agonists Market
- Based on the segmentation by product type, the Semaglutide-Based Therapies & Tirzepatide-Based Therapies segment is leading the United States GLP-1 Agonists Market in 2025, holding nearly 68% of the total market share due to strong adoption for obesity management and type 2 diabetes treatment.
- Based on the segmentation by application, the Obesity Management & Type 2 Diabetes Treatment segment accounted for approximately 74% market share in 2025, driven by increasing patient awareness, physician adoption, and expanding treatment eligibility.
- The global revenue of Eli Lilly and Company in fiscal year 2025 stood at nearly USD 65.2 billion, supported by strong sales of Mounjaro and Zepbound therapies.
- Increasing investments in next-generation incretin therapies, oral GLP-1 formulations, and precision metabolic health solutions are expected to fuel market growth, as advanced GLP-1 therapies improve long-term weight reduction outcomes by up to 25–30% while enhancing glycemic control and cardiovascular health benefits.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Pharmaceuticals & Metabolic Health
Decisions Advisors provides intelligent market research covering obesity therapeutics, diabetes management solutions, metabolic health innovations, and next-generation incretin therapies. The research identifies growth opportunities, technology adoption patterns, competitive positioning, and strategic developments within the United States GLP-1 Agonists Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research methodology utilizes primary interviews, pharmaceutical value chain assessments, healthcare provider surveys, reimbursement analysis, and data triangulation techniques to deliver accurate market sizing, CAGR forecasts, investment evaluations, and therapeutic trend analysis. The study assesses demand across obesity treatment centers, diabetes clinics, hospitals, specialty pharmacies, and telehealth platforms.
- Highly Competitive Environment Analysis
The report includes detailed evaluations of leading pharmaceutical companies, GLP-1 drug innovations, obesity treatment pipelines, strategic partnerships, clinical trial advancements, and regulatory developments. It also examines reimbursement trends, healthcare policies, and emerging opportunities within the United States GLP-1 Agonists Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States GLP-1 Agonists Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States GLP-1 Agonists Market
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer Inc.
- Amgen Inc.
- AstraZeneca plc
- Roche Holding AG
- Structure Therapeutics Inc.
- Viking Therapeutics, Inc.
- Altimmune, Inc.
- Zealand Pharma A/S
Recent Developments:
- In June 2026, Eli Lilly and Company reported positive late-stage clinical trial results for retatrutide, demonstrating significant weight-loss outcomes and reinforcing its leadership position in the obesity treatment market.
- In January 2026, Novo Nordisk A/S reported rapid adoption of its oral Wegovy formulation, surpassing three million prescriptions shortly after launch and expanding access to GLP-1 therapies.
Market Segmentation:
United States GLP-1 Agonists Market, By Product Type
- Semaglutide-Based Therapies
- Tirzepatide-Based Therapies
- Dulaglutide-Based Therapies
- Liraglutide-Based Therapies
- Emerging GLP-1 & Incretin Combination Therapies
United States GLP-1 Agonists Market, By Technology
- Injectable GLP-1 Therapies
- Oral GLP-1 Formulations
- Dual Agonist Therapies
- Triple Agonist Metabolic Therapies
- AI-Enabled Personalized Treatment Platforms
United States GLP-1 Agonists Market, By Application
- Obesity Management
- Type 2 Diabetes Treatment
- Cardiovascular Risk Reduction
- Metabolic Disorder Management
- Chronic Weight Management Programs
Expert Views:
The United States GLP-1 agonists market is expected to experience substantial growth due to rising obesity prevalence, increasing diabetes incidence, and strong clinical evidence supporting metabolic and cardiovascular benefits. The integration of oral GLP-1 therapies, next-generation incretin drugs, AI-driven patient management systems, and personalized treatment approaches will improve treatment accessibility and outcomes. Furthermore, continued innovation by major pharmaceutical companies and expanding reimbursement support are anticipated to create significant opportunities for market participants through 2035.
Author: Komal and Radhika By Spherical Insights and Consulting